Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya.

Lancet. 1996 Mar 16;347(9003):718-23. Unique Identifier : AIDSLINE MED/96181131
Gilks CF; Ojoo SA; Ojoo JC; Brindle RJ; Paul J; Batchelor BI; Kimari JN; Newnham R; Bwayo J; Plummer FA; Warrell DA; Chinical Research Centre, Kenya Medical Research Institute,; Nairobi, Kenya.


Abstract: BACKGROUND: HIV infection is a major risk factor for pneumococcal disease in industrialised countries. Although both are common infections in sub-Saharan Africa, few studies have investigated the importance of this interaction. We have followed up a cohort of female sex-workers in Nairobi and report here on the extent of invasive pneumococcal disease.METHODS: A well-established cohort of low-class female sex-workers, based around a community clinic, was followed up from October, 1989, to September, 1992. 587 participants were HIV positive and 132 remained HIV negative. Set protocols were used to investigate common presentations. Cases were identified clinically and radiographically. Streptococcus pneumoniae and other pathogens were diagnosed by culture. FINDINGS: Seventy-nine episodes of invasive pneumococcal disease were seen in the 587 HIV-positive women compared with one episode in the 132 seronegative women (relative risk 17.8, 95% CI 2.5 to 126.5). In seropositive women the incidence rate was 42.5 per 1000 person-years and the recurrence rate was 264 per 1000 person-years. By serotyping, most recurrent events were re-infection. A wide spectrum of HIV-related pneumococcal disease was seen: only 56% of cases were pneumonia; sinusitis was seen in 30% of cases, and occult bacteraemia, a novel adult presentation, in 11%. Despite forty-two bacteraemic episodes, no deaths were attributable to Strep pneumoniae. At first presentation the mean CD4 cell count was 302/microL(SD 191) and was 171/microL (105) for recurrent episodes. During acute Strep pneumoniae infection the CD4 cell count was reversibly suppressed (mean fall in sixteen episodes, 105/microL [123]). The neutrophil response to acute infection was blunted and was correlated with CD4 count (r=0.50, 95% CI 0.29 to 0.66). Strep pneumoniae caused more disease, at an earlier stage of HIV immunosuppression, than Mycobacterium tuberculosis or non-typhi salmonellae. INTERPRETATION: Our study highlights the importance of the pneumococcus as an early but readily treatable complication of HIV infection in sub-Saharan Africa.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS/IMMUNOLOGY Adult Antibiotics/THERAPEUTIC USE AIDS-Related Opportunistic Infections/DRUG THERAPY/*EPIDEMIOLOGY/ IMMUNOLOGY Bacteremia/DRUG THERAPY/EPIDEMIOLOGY/MICROBIOLOGY Cohort Studies CD4 Lymphocyte Count Female Human HIV Seronegativity HIV Seropositivity/EPIDEMIOLOGY *HIV-1 Kenya/EPIDEMIOLOGY Pneumococcal Infections/DRUG THERAPY/*EPIDEMIOLOGY/IMMUNOLOGY Pneumonia, Lobar/DRUG THERAPY/EPIDEMIOLOGY/MICROBIOLOGY *Prostitution Recurrence Sinusitis/DRUG THERAPY/EPIDEMIOLOGY/MICROBIOLOGY Support, Non-U.S. Gov't JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/KWDcomplications/immunologyadultantibiotics/therapeuticuseaids-relatedopportunisticinfections/drugtherapy/KWDepidemiology/immunologybacteremia/drugtherapy/epidemiology/microbiologycohortstudiescd4lymphocytecountfemalehumanhivseronegativityhivseropositivity/epidemiologyKWDhiv-1kenya/epidemiologypneumococcalinfections/drugtherapy/KWDepidemiology/immunologypneumonia,lobar/drugtherapy/epidemiology/microbiologyKWDprostitutionrecurrencesinusitis/drugtherapy/epidemiology/microbiologysupport,non-uKWDsKWDgov'tjournalarticle
960730
M9670443

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .